سعر ليبتوبرينول 500مجم 30 قرص ممتد المفعول 2025

Leptoprenol 500 mg 30 s.r. f.c. tabs: sodium valproate 500 mg prolonged-release film-coated tablets, pack of 30 (International Drug Agency (IDI) > Egypharma, Egypt); antiepileptic (fatty acid derivative).

• Sodium valproate (ingredient level, UK SmPC for a different formulation): treatment of generalised, partial or other epilepsy.Population: Adults and childrenelectronic medicines compendium (emc), UK

• Very common: nausea, tremor. Common: vomiting, gingival hyperplasia, stomatitis, gastralgia, diarrhoea, liver injury, extrapyramidal disorder, somnolence, memory impairment, headache, nystagmus. Uncommon: pancreatitis (sometimes fatal), encephalopathy, ataxia.General active-ingredient information · electronic medicines compendium (emc), UK

• Pregnancy, and women of childbearing potential under 55 years, unless two specialists document no alternative and the Pregnancy Prevention Programme conditions are met.General active-ingredient information · electronic medicines compendium (emc), UK
• Hypersensitivity to sodium valproate or any excipient.General active-ingredient information · electronic medicines compendium (emc), UK
• Active liver disease, or personal or family history of severe hepatic dysfunction, especially drug related.General active-ingredient information · electronic medicines compendium (emc), UK

• Severe liver damage, including fatal hepatic failure, has been reported, mostly in the first 6 months; highest risk in children under 3 years, on multiple anticonvulsants or with metabolic/mitochondrial disorders; watch for asthenia, anorexia, lethargy, vomiting and loss of seizure control.General active-ingredient information · electronic medicines compendium (emc), UK
• Pancreatitis, sometimes fatal, has been reported; discontinue valproate if pancreatitis occurs.General active-ingredient information · electronic medicines compendium (emc), UK
• Suicidal ideation and behaviour have been reported with antiepileptic drugs; monitor patients for signs.General active-ingredient information · electronic medicines compendium (emc), UK

• Carbapenems (imipenem, meropenem, panipenem)Decrease valproic acid levels by 60-100% within two days, sometimes with convulsions; co-administration should be avoided.electronic medicines compendium (emc), UK
• LamotrigineValproate reduces lamotrigine metabolism and nearly doubles its half-life, increasing toxicity risk (especially serious rash); reduce lamotrigine dose and monitor.electronic medicines compendium (emc), UK
• Salicylates (aspirin)Should not be used concomitantly (same metabolic pathway; increased risk of liver toxicity in children under 3 years).electronic medicines compendium (emc), UK

• Contraindicated in pregnancy unless two specialists independently document that there is no other effective or tolerated treatment; about 11% major congenital malformations after monotherapy exposure (vs 2-3% background) and neurodevelopmental disorders in up to 30-40%; must be prescribed under the Valproate Pregnancy Prevention Programme.General active-ingredient information · electronic medicines compendium (emc), UK
• Excreted in human milk at 1-10% of maternal serum levels; haematological disorders have been reported in breastfed infants; decide whether to stop breastfeeding or valproate therapy.General active-ingredient information · electronic medicines compendium (emc), UK

• Sodium valproate: Increases GABA availability and modulates neuronal excitability; the exact mechanism is multifactorial.